Trial reportTobacco control2006
An uncontrolled trial of cytisine (Tabex) for smoking cessation.
Trial report in Tobacco control, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- Understanding varenicline function via key receptor and ligand interactions.Cell reports. Physical science · 2025Article
- Cytisine for smoking cessation in hospitalised smokers with cardiovascular diseases: an observational study.Internal and emergency medicine · 2025Observational
- Cytisine compared to combination nicotine replacement therapy to reduce cigarette consumption in relapsed smokers: protocol for a pilot randomized controlled trial.Pilot and feasibility studies · 2025Article
- Cytisine as an Emerging Tool for Smoking Cessation and Addiction Treatment.Iranian journal of public health · 2024Article
- Cytisine as a smoking cessation aid: Preliminary observations with a modified therapeutic scheme in real life.Tumori · 2024Observational
- Cytisine for smoking cessation: A 40-day treatment with an induction period.Tobacco prevention & cessation · 2024Article
- Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.Psychopharmacology · 2017Article
- Nicotinic Acetylcholine Receptors as Targets for Tobacco Cessation Therapeutics: Cutting-Edge Methodologies to Understand Receptor Assembly and Trafficking.Neuromethods · 2016Article
- Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development.Addiction (Abingdon, England) · 2015Review
- Nicotinic receptor antagonists as treatments for nicotine abuse.Advances in pharmacology (San Diego, Calif.) · 2014Review
- A survey of tobacco dependence treatment services in 121 countries.Addiction (Abingdon, England) · 2013Article
- Current and emerging pharmacotherapeutic options for smoking cessation.Substance abuse : research and treatment · 2013Article
- Review
- Review
- Nicotinic receptor-based therapeutics and candidates for smoking cessation.Biochemical pharmacology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCytisine (Tabex) has been licensed in Eastern Europe as an aid to smoking cessation for 40 years. Cytisine is a partial agonist with high affinity binding to the alpha4beta2 nicotinic acetylcholine receptor believed to be central to the rewarding effect of nicotine. There is insufficient information on effectiveness to warrant licensing by modern standards. To assess whether full-scale controlled trials are warranted, this study sought to obtain an estimate of the 12-month continuous abstinence rates of smokers using cytisine with minimal behavioural support.
designAn uncontrolled, open-label trial.
settingA smokers' clinic in an oncology centre in Warsaw, Poland. SUBJECTS: 436 consecutive attendees of the smokers' clinic of whom 191 were male. The mean dependence score (Fagerstrom Test for Nicotine Dependence) was 6.1.
interventionThe standard regimen of Tabex (cytisine) was used, involving 25 days of treatment with minimal behavioural support.
main outcome measureSelf-reported continuous abstinence for 12 months; with abstinence verified by carbon monoxide at the final follow up (after 12 months).
results60 participants (13.8% of the total sample) were abstinent for 12 months. Of the 315 subjects, who had taken the drug, 49 (15.5%) stopped cytisine because of adverse effects (mostly gastric disturbances and nausea), although they were not serious. The frequency of the minor adverse effects, primarily gastric disturbance, was similar to that observed in previous studies with the drug.
conclusionsThe long-term abstinence rates were similar to those observed in smokers receiving nicotine replacement therapy. Full-scale randomised trials of cytisine (Tabex), conducted to the standards required by regulatory authorities, are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.